FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Fund ProfileVirtus LifeSci Biotech Clinical Trials ETF
  • Fund Overview
  • Fund Data
  • Peer Comparison
  • Ownership & News
BBC
Virtus LifeSci Biotech Clinical Trials ETF ETF AnalysisComprehensive ETF analysis for Virtus LifeSci Biotech Clinical Trials ETF (BBC) including NAV, expense ratio, dividend yield, sector breakdown, and holdings data.ETF AnalysisBBC
BBC
Virtus LifeSci Biotech Clinical Trials ETF
  • Fund Overview
  • Fund Data
  • Peer Comparison
  • Ownership & News
BBC
  1. Home
  2. Screener
  3. Virtus LifeSci Biotech Clinical Trials ETFBBCETF

Virtus LifeSci Biotech Clinical Trials ETF

ETF
🇺🇸BBC•AMEX•Sector Equity
Fund size (USD)
$32.26M
Expense Ratio
0.65%
Yield (12 mo)
1.65%
Holdings
198

Your view on BBC

Virtus LifeSci Biotech Clinical Trials ETF

ETFVirtus
🇺🇸BBC•AMEX•Sector Equity
Fund size (USD)
$32.26M
Expense Ratio
0.65%
Yield (12 mo)
1.65%
Holdings
198
Your view
Fund Overview

Overview

What the fund invests in, who runs it, and what it costs.

Virtus LifeSci Biotech Clinical Trials ETF (BBC) is a Sector Equity fund from Virtus, listed since 2014, with $32.3M in assets under management, a 0.65% expense ratio and a NAV of $43.01 USD.

Overview for Virtus LifeSci Biotech Clinical Trials ETF

Fund Type
ETF
Fund Issuer
Virtus
Asset Class
Sector Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
December 16, 2014
Domicile
US
Website
virtus.com/products/virtus-biotech-clinical-trials-etf#shareclass./period.quarterly
Fund Type
ETF
Fund Issuer
Virtus
Asset Class
Sector Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
December 16, 2014
Domicile
US
Website
virtus.com/products/virtus-biotech-clinical-trials-etf#shareclass./period.quarterly
Fund Type
ETF
Fund Issuer
Virtus
Asset Class
Sector Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
December 16, 2014
Domicile
US
Website
virtus.com/products/virtus-biotech-clinical-trials-etf#shareclass./period.quarterly

About this fund

The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index, which tracks the performance of select clinical trials stage biotechnology companies.

Fund Data

Price Chart

Market price history and trading volume.

Key Facts

Cost, yield, size, and the fund's reference data.

Sector Equity

Expense Ratio

0.65%

Yield (12 mo)

1.65%

Fund size

$32.26M

Fund Details

NAV$43.01 USD
Holdings198
Average Volume28.5K
Inception DateDecember 16, 2014
Asset ClassSector Equity
Fund IssuerVirtus
DomicileUS
ISINUS26923G3011
CUSIP26923G301
NAV CurrencyUSD

Expense Ratio

0.65%

Dividend Yield (TTM)

1.65%

Assets Under Management

$32.26M

NAV

$43.01 USD

Holdings

198

Average Volume

28.5K

Inception Date

December 16, 2014

Asset Class

Sector Equity

Fund Issuer

Virtus

Domicile

US

ISIN

US26923G3011

CUSIP

26923G301

NAV Currency

USD

Expense Ratio

0.65%

Dividend Yield (TTM)

1.65%

Assets Under Management

$32.26M

NAV

$43.01 USD

Holdings

198

Average Volume

28.5K

Inception Date

December 16, 2014

Asset Class

Sector Equity

Fund Issuer

Virtus

Domicile

US

ISIN

US26923G3011

CUSIP

26923G301

NAV Currency

USD

Distributions · last 12 months

Annual · 1 payment

Ex-datePaidAmount
Dec 22, 2025Dec 29, 2025$0.6554
Total, 12 months$0.66 a share

Dividend yield (TTM) 1.65% = $0.66 paid per share in the 12 months to Nov 20, 2026 ÷ the $39.77 price. Past distributions; future payments can differ.

Data last updated: Nov 15, 2026, 08:10 AM

Sectors

How the fund's assets are split across sectors.

1 sectors
  • 1Healthcare
    100.0%

Top sector

Healthcare

Top weight

100.0%

Top 3 weight

100.0%

Holdings

The securities the fund owns, by weight.

130 positions
1KODKodiak Sciences Inc
2.41%
2XNCRXencor Inc
2.31%
3TRAXFirst Tracks Biotherapeutics Inc
2.12%
4REPLReplimune Group Inc
1.82%
5ABCLAbCellera Biologics Inc
1.68%
6VRDNViridian Therapeutics Inc
1.61%
7SLSSELLAS Life Sciences Group Inc
1.59%
8AMLXAmylyx Pharmaceuticals Inc
1.51%
9SGPSpyGlass Pharma Inc
1.40%
10MBXMBX Biosciences Inc
1.26%
11LBRXLB Pharmaceuticals Inc
1.18%
12ORKAOruka Therapeutics Inc
1.17%
13KYMRKymera Therapeutics Inc
1.16%
14PRMEPrime Medicine Inc
1.16%
15CGONCG Oncology Inc
1.15%

Concentration

Top 10 Weight17.71%
1KODKodiak Sciences Inc
2.41%
2XNCRXencor Inc
2.31%
3TRAXFirst Tracks Biotherapeutics Inc
2.12%
4REPLReplimune Group Inc
1.82%
5ABCLAbCellera Biologics Inc
1.68%
6VRDNViridian Therapeutics Inc
1.61%
7SLSSELLAS Life Sciences Group Inc
1.59%
8AMLXAmylyx Pharmaceuticals Inc
1.51%
9SGPSpyGlass Pharma Inc
1.40%
10MBXMBX Biosciences Inc
1.26%
11LBRXLB Pharmaceuticals Inc
1.18%
12ORKAOruka Therapeutics Inc
1.17%
13KYMRKymera Therapeutics Inc
1.16%
14PRMEPrime Medicine Inc
1.16%
15CGONCG Oncology Inc
1.15%

Top 10 Weight

17.71%

1KODKodiak Sciences Inc
2.41%$767.4K
2XNCRXencor Inc
2.31%$736.4K
3TRAXFirst Tracks Biotherapeutics Inc
2.12%$672.9K
4REPLReplimune Group Inc
1.82%$578.1K
5ABCLAbCellera Biologics Inc
1.68%$533.4K
6VRDNViridian Therapeutics Inc
1.61%$513.4K
7SLSSELLAS Life Sciences Group Inc
1.59%$506.7K
8AMLXAmylyx Pharmaceuticals Inc
1.51%$479.4K
9SGPSpyGlass Pharma Inc
1.40%$445.6K
10MBXMBX Biosciences Inc
1.26%$401.6K
11LBRXLB Pharmaceuticals Inc
1.18%$376.1K
12ORKAOruka Therapeutics Inc
1.17%$372.7K
13KYMRKymera Therapeutics Inc
1.16%$369.8K
14PRMEPrime Medicine Inc
1.16%$369.4K
15CGONCG Oncology Inc
1.15%$367.3K

Top 10 Weight

17.71%

Peer Comparison

Comparables

Funds similar to this one.

Side by side on what an ETF is compared on19 funds
FundAsset classExpense ratioAssetsHoldings
BBCVirtus LifeSci Biotech Clinical Trials ETFThis fundSector Equity0.65%$32M198

Comparable funds

  • BWTGBrendan Wood TopGun ETFEquity0.98%$20M22
  • FLNFirst Trust Latin America AlphaDEX FundInternational Equity0.80%$110M50
  • FTXGFirst Trust Nasdaq Food & Beverage ETFSector Equity0.60%$39M30
  • HELXFranklin Genomic Advancements ETFEquity0.50%$33M63
  • MEDXHorizon Kinetics Medical ETFEquity0.85%$18M32
  • PATNPacer Nasdaq International Patent Leaders ETFEquity0.65%$381M108
  • QIGWisdomTree U.S. Corporate Bond FundFixed Income0.18%$17M490

More Virtus ETFs

  • PFFAVirtus InfraCap U.S. Preferred Stock ETFCore Investment Grade Bond2.11%$2.2B198
  • PFFRInfraCap REIT Preferred ETFReal Estate (Listed/REITs)0.45%$108M110
  • SDCPVirtus Newfleet Short Duration Core Plus Bond ETFFixed Income0.35%$13M198
  • SEIXVirtus Seix Senior Loan ETFHigh Yield & Loans0.57%$307M198
  • SSMGVirtus Silvant Small/Mid Growth ETFUS Equity0.39%$3M82
  • UTESVirtus Reaves Utilities ETFAlternatives0.49%$1.1B198
  • VABSVirtus Newfleet Securitized Income ETFCore Investment Grade Bond0.39%$113M198
  • VCLNVirtus Duff & Phelps Clean Energy ETFSector Equity0.59%$5M189
  • VDIVirtus International Dividend ETFInternational Equity0.39%$16M121
  • VEMVirtus Emerging Markets Dividend ETFInternational Equity0.49%$6M57
  • VEMYVirtus Stone Harbor Emerging Markets High Yield Bond ETFEmerging Market Bond0.55%$36M189
  • VGROVirtus Silvant Growth Opportunities ETFUS Equity0.35%$4M22
Ownership & News

Fund Holders

Institutions that own shares of this fund.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for this company. Press releases and market coverage, newest first.